Research ExplorerPublicationsPredictors of early morbidity and mortality in newly diagnos...

Predictors of early morbidity and mortality in newly diagnosed multiple myeloma: results from the EPICOVIDEHA survey

Standard

Predictors of early morbidity and mortality in newly diagnosed multiple myeloma: results from the EPICOVIDEHA survey. / Mai, Elias K; Hielscher, Thomas; Bertsch, Uta; Salwender, Hans J; Zweegman, Sonja; Raab, Marc S; Munder, Markus; Pantani, Lucia; Mancuso, Katia; Brossart, Peter; Beksac, Meral; Blau, Igor W; Dürig, Jan; Besemer, Britta; Fenk, Roland; Reimer, Peter; van der Holt, Bronno; Hänel, Mathias; von Metzler, Ivana; Graeven, Ullrich; Müller-Tidow, Carsten; Boccadoro, Mario; Scheid, Christof; Dimopoulos, Meletios A; Hillengass, Jens; Weisel, Katja C; Cavo, Michele; Sonneveld, Pieter; Goldschmidt, Hartmut.

In: LEUKEMIA, Vol. 38, No. 3, 03.2024, p. 640-647.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Mai, EK, Hielscher, T, Bertsch, U, Salwender, HJ, Zweegman, S, Raab, MS, Munder, M, Pantani, L, Mancuso, K, Brossart, P, Beksac, M, Blau, IW, Dürig, J, Besemer, B, Fenk, R, Reimer, P, van der Holt, B, Hänel, M, von Metzler, I, Graeven, U, Müller-Tidow, C, Boccadoro, M, Scheid, C, Dimopoulos, MA, Hillengass, J, Weisel, KC, Cavo, M, Sonneveld, P & Goldschmidt, H 2024, 'Predictors of early morbidity and mortality in newly diagnosed multiple myeloma: results from the EPICOVIDEHA survey', LEUKEMIA, vol. 38, no. 3, pp. 640-647. https://doi.org/10.1038/s41375-023-02105-6

APA

Mai, E. K., Hielscher, T., Bertsch, U., Salwender, H. J., Zweegman, S., Raab, M. S., Munder, M., Pantani, L., Mancuso, K., Brossart, P., Beksac, M., Blau, I. W., Dürig, J., Besemer, B., Fenk, R., Reimer, P., van der Holt, B., Hänel, M., von Metzler, I., ... Goldschmidt, H. (2024). Predictors of early morbidity and mortality in newly diagnosed multiple myeloma: results from the EPICOVIDEHA survey. LEUKEMIA, 38(3), 640-647. https://doi.org/10.1038/s41375-023-02105-6

Vancouver

Mai EK, Hielscher T, Bertsch U, Salwender HJ, Zweegman S, Raab MS et al. Predictors of early morbidity and mortality in newly diagnosed multiple myeloma: results from the EPICOVIDEHA survey. LEUKEMIA. 2024 Mar;38(3):640-647. https://doi.org/10.1038/s41375-023-02105-6

Bibtex

@article{5163cf30b4614226a2996ba9fc1b2f34,
title = "Predictors of early morbidity and mortality in newly diagnosed multiple myeloma: results from the EPICOVIDEHA survey",
abstract = "Early morbidity and mortality affect patient outcomes in multiple myeloma. Thus, we dissected the incidence and causes of morbidity/mortality during induction therapy (IT) for newly diagnosed multiple myeloma (NDMM), and developed/validated a predictive risk score. We evaluated 3700 transplant-eligible NDMM patients treated in 2005-2020 with novel agent-based triplet/quadruplet IT. Primary endpoints were severe infections, death, or a combination of both. Patients were divided in a training (n = 1333) and three validation cohorts (n = 2367). During IT, 11.8%, 1.8%, and 12.5% of patients in the training cohort experienced severe infections, death, or both, respectively. Four major, baseline risk factors for severe infection/death were identified: low platelet count (<150/nL), ISS III, higher WHO performance status (>1), and age (>60 years). A risk score (1 risk factor=1 point) stratified patients in low (39.5%; 0 points), intermediate (41.9%; 1 point), and high (18.6%; ≥2 points) risk. The risk for severe infection/death increased from 7.7% vs. 11.5% vs. 23.3% in the low- vs. intermediate- vs. high-risk groups (p < 0.001). The risk score was independently validated in three trials incorporating quadruplet IT with an anti-CD38 antibody. Our analyses established a robust and easy-to-use score to identify NDMM patients at risk of severe infection/death, covering the latest quadruplet induction therapies. Trial registrations: HOVON-65/GMMG-HD4: EudraCT No. 2004-000944-26. GMMG-MM5: EudraCT No. 2010-019173-16. GMMG-HD6: NCT02495922. EMN02/HOVON-95: NCT01208766. GMMG-HD7: NCT03617731.",
author = "Mai, {Elias K} and Thomas Hielscher and Uta Bertsch and Salwender, {Hans J} and Sonja Zweegman and Raab, {Marc S} and Markus Munder and Lucia Pantani and Katia Mancuso and Peter Brossart and Meral Beksac and Blau, {Igor W} and Jan D{\"u}rig and Britta Besemer and Roland Fenk and Peter Reimer and {van der Holt}, Bronno and Mathias H{\"a}nel and {von Metzler}, Ivana and Ullrich Graeven and Carsten M{\"u}ller-Tidow and Mario Boccadoro and Christof Scheid and Dimopoulos, {Meletios A} and Jens Hillengass and Weisel, {Katja C} and Michele Cavo and Pieter Sonneveld and Hartmut Goldschmidt",
note = "{\textcopyright} 2023. The Author(s).",
year = "2024",
month = mar,
doi = "10.1038/s41375-023-02105-6",
language = "English",
volume = "38",
pages = "640--647",
journal = "LEUKEMIA",
issn = "0887-6924",
publisher = "NATURE PUBLISHING GROUP",
number = "3",

}

RIS

TY - JOUR

T1 - Predictors of early morbidity and mortality in newly diagnosed multiple myeloma: results from the EPICOVIDEHA survey

AU - Mai, Elias K

AU - Hielscher, Thomas

AU - Bertsch, Uta

AU - Salwender, Hans J

AU - Zweegman, Sonja

AU - Raab, Marc S

AU - Munder, Markus

AU - Pantani, Lucia

AU - Mancuso, Katia

AU - Brossart, Peter

AU - Beksac, Meral

AU - Blau, Igor W

AU - Dürig, Jan

AU - Besemer, Britta

AU - Fenk, Roland

AU - Reimer, Peter

AU - van der Holt, Bronno

AU - Hänel, Mathias

AU - von Metzler, Ivana

AU - Graeven, Ullrich

AU - Müller-Tidow, Carsten

AU - Boccadoro, Mario

AU - Scheid, Christof

AU - Dimopoulos, Meletios A

AU - Hillengass, Jens

AU - Weisel, Katja C

AU - Cavo, Michele

AU - Sonneveld, Pieter

AU - Goldschmidt, Hartmut

N1 - © 2023. The Author(s).

PY - 2024/3

Y1 - 2024/3

N2 - Early morbidity and mortality affect patient outcomes in multiple myeloma. Thus, we dissected the incidence and causes of morbidity/mortality during induction therapy (IT) for newly diagnosed multiple myeloma (NDMM), and developed/validated a predictive risk score. We evaluated 3700 transplant-eligible NDMM patients treated in 2005-2020 with novel agent-based triplet/quadruplet IT. Primary endpoints were severe infections, death, or a combination of both. Patients were divided in a training (n = 1333) and three validation cohorts (n = 2367). During IT, 11.8%, 1.8%, and 12.5% of patients in the training cohort experienced severe infections, death, or both, respectively. Four major, baseline risk factors for severe infection/death were identified: low platelet count (<150/nL), ISS III, higher WHO performance status (>1), and age (>60 years). A risk score (1 risk factor=1 point) stratified patients in low (39.5%; 0 points), intermediate (41.9%; 1 point), and high (18.6%; ≥2 points) risk. The risk for severe infection/death increased from 7.7% vs. 11.5% vs. 23.3% in the low- vs. intermediate- vs. high-risk groups (p < 0.001). The risk score was independently validated in three trials incorporating quadruplet IT with an anti-CD38 antibody. Our analyses established a robust and easy-to-use score to identify NDMM patients at risk of severe infection/death, covering the latest quadruplet induction therapies. Trial registrations: HOVON-65/GMMG-HD4: EudraCT No. 2004-000944-26. GMMG-MM5: EudraCT No. 2010-019173-16. GMMG-HD6: NCT02495922. EMN02/HOVON-95: NCT01208766. GMMG-HD7: NCT03617731.

AB - Early morbidity and mortality affect patient outcomes in multiple myeloma. Thus, we dissected the incidence and causes of morbidity/mortality during induction therapy (IT) for newly diagnosed multiple myeloma (NDMM), and developed/validated a predictive risk score. We evaluated 3700 transplant-eligible NDMM patients treated in 2005-2020 with novel agent-based triplet/quadruplet IT. Primary endpoints were severe infections, death, or a combination of both. Patients were divided in a training (n = 1333) and three validation cohorts (n = 2367). During IT, 11.8%, 1.8%, and 12.5% of patients in the training cohort experienced severe infections, death, or both, respectively. Four major, baseline risk factors for severe infection/death were identified: low platelet count (<150/nL), ISS III, higher WHO performance status (>1), and age (>60 years). A risk score (1 risk factor=1 point) stratified patients in low (39.5%; 0 points), intermediate (41.9%; 1 point), and high (18.6%; ≥2 points) risk. The risk for severe infection/death increased from 7.7% vs. 11.5% vs. 23.3% in the low- vs. intermediate- vs. high-risk groups (p < 0.001). The risk score was independently validated in three trials incorporating quadruplet IT with an anti-CD38 antibody. Our analyses established a robust and easy-to-use score to identify NDMM patients at risk of severe infection/death, covering the latest quadruplet induction therapies. Trial registrations: HOVON-65/GMMG-HD4: EudraCT No. 2004-000944-26. GMMG-MM5: EudraCT No. 2010-019173-16. GMMG-HD6: NCT02495922. EMN02/HOVON-95: NCT01208766. GMMG-HD7: NCT03617731.

U2 - 10.1038/s41375-023-02105-6

DO - 10.1038/s41375-023-02105-6

M3 - SCORING: Journal article

C2 - 38062124

VL - 38

SP - 640

EP - 647

JO - LEUKEMIA

JF - LEUKEMIA

SN - 0887-6924

IS - 3

ER -